S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Mind Medicine (MindMed) News Headlines

-0.01 (-1.91%)
(As of 06/29/2022 08:58 PM ET)
Today's Range
50-Day Range
52-Week Range
1.64 million shs
Average Volume
3.83 million shs
Market Capitalization
$281.77 million
P/E Ratio
Dividend Yield
Price Target
Get Mind Medicine (MindMed) News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter.

MNMD Media Mentions By Week

MNMD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

News Sentiment



News Sentiment

MNMD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MNMD Articles
This Week



MNMD Articles
Average Week

MNMD Stock News Headlines Today

MarketBeat logoMind Medicine (MindMed) Inc. (NASDAQ:MNMD) CEO Robert Barrow Sells 36,762 Shares
americanbankingnews.com - June 29 at 5:28 AM
MarketBeat logoMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Insider Dan Karlin Sells 26,238 Shares of Stock
americanbankingnews.com - June 29 at 5:28 AM
MarketBeat logoRobert Barrow Sells 21,275 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Stock
americanbankingnews.com - June 23 at 5:48 AM
MarketBeat logoMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Recommendation of "Buy" from Analysts
americanbankingnews.com - June 15 at 2:50 AM
finance.yahoo.com logoMindmed Announces Voting Results for Annual General and Special Meeting
finance.yahoo.com - June 1 at 5:35 PM
finance.yahoo.com logoIIROC Trading Halt - MMED.WT
finance.yahoo.com - May 26 at 12:59 PM
marketwatch.com logoMind Medicine Names Schond Greenway as Financial Chief >MNMD
marketwatch.com - May 23 at 8:57 AM
nasdaq.com logoMindMed Names Schond Greenway As CFO
nasdaq.com - May 23 at 8:57 AM
finance.yahoo.com logoMindMed Appoints Schond L. Greenway as Chief Financial Officer
finance.yahoo.com - May 23 at 8:57 AM
nasdaq.com logoMind Medicine: Focusing on Treatments, Not Revenue
nasdaq.com - May 19 at 10:15 PM
finance.yahoo.com logoMindMed Reports First Quarter 2022 Financial Results and Business Highlights
finance.yahoo.com - May 16 at 8:53 AM
nasdaq.com logoWhy Earnings Season Could Be Great for Mind Medicine (MNMD)
nasdaq.com - May 12 at 1:33 PM
finance.yahoo.com logoMindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management
finance.yahoo.com - May 12 at 7:46 AM
finance.yahoo.com logoMindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
finance.yahoo.com - May 11 at 11:45 AM
finance.yahoo.com logoMindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business Update
finance.yahoo.com - May 9 at 9:38 AM
finanznachrichten.de logoMicrosmallcap.com: Oregon to Become the First State to Legally Roll Out Psilocybin
finanznachrichten.de - April 28 at 9:11 AM
markets.businessinsider.com logoEXCLUSIVE: Why Kevin O'Leary Of 'Shark Tank' Says Public Psychedelics Companies Will Need To Merge
markets.businessinsider.com - April 19 at 2:14 PM
finance.yahoo.com logoMindMed CEO: ‘We see a massive opportunity’ in the psychedelic medicine industry
finance.yahoo.com - April 7 at 9:34 PM
markets.businessinsider.com logoMindMed Appoints Francois Lilienthal As New CCO
markets.businessinsider.com - April 5 at 7:17 PM
finance.yahoo.com logoMindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer
finance.yahoo.com - April 5 at 10:04 AM
benzinga.com logoNovamind To Host MindMed Phase IIb Trial For LSD Based Drug For Anxiety Treatment
benzinga.com - March 16 at 4:29 PM
finanznachrichten.de logoNovamind Inc.: Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
finanznachrichten.de - March 16 at 11:28 AM
finance.yahoo.com logoMindMed to Participate in March Investor Conferences
finance.yahoo.com - March 9 at 11:18 AM
finance.yahoo.com logoMindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects
finance.yahoo.com - March 2 at 8:08 AM
benzinga.com logoMindMed Converts Shares To Have A Single Class
benzinga.com - February 23 at 11:19 AM
seekingalpha.com logoMindMed gets FDA OK to start trial for pharmacological LSD in anxiety disorder
seekingalpha.com - January 25 at 12:20 PM
nasdaq.com logoWhy MindMed Is Rising In Pre-market?
nasdaq.com - January 25 at 12:20 PM
markets.businessinsider.com logoWhy Mind Medicine Shares Are Rising Today
markets.businessinsider.com - January 25 at 12:20 PM
seekingalpha.com logoMindMed begins enrollment in Session Monitoring System study for sensory data
seekingalpha.com - January 18 at 3:33 PM
finance.yahoo.com logoMindMed Enrolls First Participant in a Study of its Session Monitoring System
finance.yahoo.com - January 18 at 10:32 AM
finance.yahoo.com logoStephen Hurst Resigns from MindMed Board of Directors
finance.yahoo.com - January 7 at 7:25 PM
markets.businessinsider.com logoMindMed Completes Phase 1 Clinical Trial Of Non-Hallucinogenic Proprietary Derivative Of Ibogaine
markets.businessinsider.com - January 6 at 5:15 AM
nasdaq.com logoDo Options Traders Know Something About MindMed (MNMD) Stock We Don't?
nasdaq.com - December 28 at 1:28 PM
nasdaq.com logoMindMed: FDA Issues Clinical Hold On Initial IND Submission Related To Phase 2b Trial Of LSD
nasdaq.com - December 22 at 3:33 AM
nasdaq.com logoMindMed Names Robert Barrow New CEO; Vallone To Replace Dellelce As Chairman
nasdaq.com - December 14 at 8:41 AM
msn.com logoEXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline
msn.com - December 11 at 2:34 PM
finance.yahoo.com logoMindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin
finance.yahoo.com - November 30 at 10:05 AM
stocknews.com logo3 Psychedelics Stocks Wall Street Predicts Will Soar
stocknews.com - November 24 at 11:13 AM
finance.yahoo.com logoMindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures
finance.yahoo.com - November 16 at 8:55 AM
finance.yahoo.com logoMindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline
finance.yahoo.com - November 15 at 9:18 AM
finance.yahoo.com logoMindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board
finance.yahoo.com - November 5 at 8:49 AM
finance.yahoo.com logoMindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program
finance.yahoo.com - October 26 at 10:24 AM
finance.yahoo.com logoMindMed Joins Clinical Trials Transformation Initiative
finance.yahoo.com - October 21 at 10:42 AM
finanznachrichten.de logoOilPrice.com: Two Trillion-Dollar Industries Being Transformed By Tech
finanznachrichten.de - October 20 at 8:43 AM
finance.yahoo.com logoMindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton
finance.yahoo.com - September 30 at 8:05 AM
finance.yahoo.com logoMindMed to present at the Benzinga Healthcare Small Cap Conference
finance.yahoo.com - September 28 at 9:09 AM
wsj.com logoMind Medicine (MindMed) Inc.
wsj.com - September 14 at 10:59 PM
finance.yahoo.com logoMindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes
finance.yahoo.com - September 2 at 9:10 AM
seekingalpha.com logoMind Medicine: Short-Term Catalysts Fall Flat
seekingalpha.com - August 24 at 6:10 PM
finance.yahoo.com logoMindMed Interim CEO on the growing competition in psychedelics industry
finance.yahoo.com - July 29 at 3:03 PM
Get Mind Medicine (MindMed) News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:MNMD) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.